Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tumor lysis syndrome.

Ramon V Tiu1, Stavros E Mountantonakis, Andrew J Dunbar

  • 1Internal Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA.

Seminars in Thrombosis and Hemostasis
|May 26, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intravascular Hemolysis and Pulsed-Field Ablation: State of the Art Review.

JACC. Clinical electrophysiology·2026
Same author

Same day discharge can be performed safely after atrial fibrillation catheter ablation using a wide-footprint lattice-tip dual-energy system.

Heart rhythm O2·2026
Same author

Practice patterns for anticoagulation monitoring after successful typical flutter ablation and related outcomes: An ITHACA-Database study.

Heart rhythm·2026
Same author

Long-Term Outcomes After Catheter Ablation: A 42-Month Longitudinal Study From the ITHACA-Database.

Journal of cardiovascular electrophysiology·2026
Same author

Impact of linear ablation in persistent atrial fibrillation using a dual-energy, wide-footprint catheter: Analysis from the SPHERE Per-AF randomized trial.

Heart rhythm·2026
Same author

Balloon-in-Basket Pulsed Field Ablation for Pulmonary Vein Isolation: 1-Year Outcomes of the VOLT-AF IDE Study.

JACC. Clinical electrophysiology·2026
Same journal

Bridging the Gap in Laboratory Monitoring of Extended Half-Life Factor VIII and IX: Can Thrombin Generation Assays Overcome Assay Discrepancies?

Seminars in thrombosis and hemostasis·2026
Same journal

External Quality Assessment for Low Molecular Weight Heparin Monitoring in the Australasia/Asia-Pacific Region.

Seminars in thrombosis and hemostasis·2026
Same journal

Human evolution: between hemorrhage and thrombosis.

Seminars in thrombosis and hemostasis·2026
Same journal

Full- vs Reduced-Dose Direct Oral Anticoagulants for Extended Treatment of Cancer-Associated Thrombosis: A Multicenter Retrospective Cohort Study.

Seminars in thrombosis and hemostasis·2026
Same journal

Too Old for PESI?: Risk Stratification of Octogenarians with Pulmonary Embolism in the Emergency Department.

Seminars in thrombosis and hemostasis·2026
Same journal

Acute Management and Bleeding Outcomes in Pediatric Pulmonary Embolism: A Large Single-Center Retrospective Cohort Study.

Seminars in thrombosis and hemostasis·2026
See all related articles

Early identification of high-risk patients is crucial for managing tumor lysis syndrome (TLS), a metabolic disorder common in cancers. Advances in urate metabolism, new drugs, and biomarkers improve TLS prophylaxis and treatment.

Area of Science:

  • Oncology
  • Nephrology
  • Pharmacology

Background:

  • Tumor lysis syndrome (TLS) is a critical metabolic complication in cancer treatment, particularly lymphoma, leukemia, and neuroblastoma.
  • Delayed recognition of TLS can lead to severe biochemical imbalances, potentially causing renal failure, arrhythmias, and seizures.
  • Proactive identification and management of high-risk individuals are essential for effective TLS prophylaxis and treatment.

Purpose of the Study:

  • To review recent advancements in understanding and managing tumor lysis syndrome (TLS).
  • To highlight new urate-lowering agents, biomarkers, and risk assessment tools for TLS.
  • To explore novel mechanisms contributing to TLS-related renal injury.

Main Methods:

  • Review of current literature on urate metabolism, transporters (URAT-1, OAT1/3, MRP4), and elimination pathways.

Related Experiment Videos

  • Comparison of traditional (allopurinol, native uricase) and novel urate-lowering drugs (febuxostat, Y-700, PEG-uricase, rasburicase).
  • Evaluation of new biomarkers (cystatin-C, NGAL, KIM1), eGFR, and prognostic models (e.g., Penn Predictive Score) for high-risk patient identification.

    • Main Results:

    • Emerging understanding of urate transporters and pathways offers new therapeutic targets.
    • Novel urate-lowering agents demonstrate improved efficacy and safety profiles compared to older drugs.
    • Advanced biomarkers and predictive models enhance the identification of patients at high risk for TLS.
    • Potential roles of asymmetric dimethylarginine and adenosine in TLS-induced renal injury warrant further investigation.

    Conclusions:

    • Recent scientific progress significantly enhances the ability to identify high-risk patients for tumor lysis syndrome.
    • New urate-lowering drugs and improved risk stratification tools are transforming TLS management.
    • Further research into novel mechanisms may uncover additional strategies for preventing and treating TLS-related complications.